Novavax’s flu data showcase vaccine platform’s potential

Pivotal data for Novavax’s flu vaccine provide validation of its recombinant nanoparticle vaccine platform as the biotech turns its technology towards developing a COVID-19 vaccine.

Novavax Inc. (NASDAQ:NVAX) added $2.01 (19%) to $12.77

Read the full 321 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE